



Biological treatment of micropollutants with eXeno™



Biological treatment of micropollutants

Micropollutants such as pharmaceuticals, personal care products or industrial chemical compounds are a large class of pollutants sometimes referred to as emerging contaminants which are typically difficult to degrade compounds. The growing risk that these compounds find their way into our water supply system and additionally, the increasing spread of antibiotic resistance genes into the environment, places growing importance on the removal of antibiotics and other difficult compounds from both industry and municipalities.

The major sources of pharmaceuticals and other difficult compounds in wastewater are:

- Household Consumption of medicines
- Chemical industries
- Hospitals

The biggest contribution of pharmaceuticals into municipal wastewater treatment plant comes from the daily consumption of pharmaceuticals in the household. Medications taken at home leave our bodies and make their way to the local municipal wastewater treatment plant where, if left untreated, they will begin to accumulate.



Chemical industries and hospitals (i.e. medication, x-ray contrast media, chemotherapy treatment) also contribute to the accumulation of micropollutants at our municipal wastewater treatment plants. All rely on the municipality to treat the effluent that is leaving their facilities.


An AnoxKaldnes micropollutant solution

eXeno™ is a technology based on AnoxKaldnes™ MBBR (Moving Bed Bio Reactor) for the biological removal of drug and other complex compound residuals in wastewater. The technology is effective, economical and environmentally friendly.

The MBBR technology relies on microorganisms, as bacteria, growing on plastic carriers which are retained in the reactor. MBBR technology allows the development of biomass with significantly longer sludge retention times (SRT) compared to conventional systems. This encourages the development of slower growing organisms capable of removing difficult compounds.

eXeno™ MBBR technology typically involves multiple reactors in series where the microorganisms can be specialised to target the wide variety of complex compounds. In the first stages, more easily degradable compounds will be removed while the more difficult compounds are removed in the succeeding reactors. The low load condition allows the development of specific microorganisms capable of degrading the more complex compounds.

Development of intelligent bacteria in eXeno™



eXeno™ benefits

Effective

High removal (50-80%) of difficult degradable pharmaceuticals

Economical

Using more bacteria and less ozone and/or activated carbon, the cost of energy and chemical usage is reduced

Environmentally friendly

Avoiding the release of by-products typical of advanced treatment reduced

Proven technology with broad application

eXeno™ is based on more than 30 years of experience of AnoxKaldnes in wastewater treatment from pharmaceutical production. With more than 25 references worldwide AnoxKaldnes has gained the expertise for treating these complex compounds. eXeno™ technologies ranges from complete treatment of pharmaceutical/industrial wastewater, and hospital wastewater to a tertiary solution for municipal applications.

eXeno-P and eXeno-H are typically full treatment systems including carbon and nitrogen removal in addition to the micropollutants.


eXeno™-M for municipal wastewater is the newly launched patented solution for post-treatment of municipal treatment plant for removal of drug residual due in anticipation of upcoming regulations. eXeno™-M is based on several years of successful research and pilot testing.

Treatment systems

Pharmaceutical = eXeno™-P


Hospital = eXeno™-H

Municipal = eXeno™-M




Patented technology for post treatment of municipal wastewater

For post-treatment of municipal wastewater, eXeno-M is based on a cyclic operation of three MBBR reactors. Effluent wastewater from the municipal wastewater treatment plant is continuously treated in a “main treatment line” which comprises two MBBR in series. The two MBBR reactors are intermittently exposed to high loaded wastewater (e.g. influent wastewater) during so called “regeneration phase” through a third MBBR reactor. During the “regeneration phase”, the biomass is exposed to a higher load which allows for more biomass growth and promotes biodiversity. The regenerated reactor is then used as a reactor one in the main treatment line. The regenerated reactor is then used as a reactor one in the main treatment line.



eXeno™ operation


- Regeneration phase every 6-48 hours.
- 5-20% of WWTP influent flow by-passed to regeneration line.
- Intermittent aeration allows for nitrification and denitrification in the regeneration line for effluent to be returned in secondary clarification.



Eliminating a broad range of compounds

More than 30 pharmaceuticals and other difficult substances were intensely studied in three different teXeno-M pilot studies. Degradation tests indicated removal of the substances ranging between 20 - 100% with reaction rates much higher when compared to other biological systems.

Pharmaceuticals known to be highly recalcitrant like iohexol, a common contrast agent for X-ray and generally not biodegradable by activated sludge, was removed up to 70%. Diclofenac, an anti-inflammatory drug raising high interest for toxic effects to the environment, can be removed in eXeno™-M up to 40%.



Indicator compounds and their maximum expected removal with eXeno™-M

Combining eXeno™ and ozone for efficient polishing

Biological removal of drug residue is an effective and environmentally friendly process. By optimising the biological degradation it is possible to limit the consumption of chemicals such as ozonation or the use of expensive physical processes such as activated carbon. However, some of the existing micropollutants found in wastewater can have low biodegradability and therefore the combination of different removal processes can be necessary. eXenoO₃™ combines biological degradation with the efficiency of oxidation. eXeno™ can be combined as a biological pre-treatment to ozonation to decrease the ozone dosage which results in both capex and opex savings. In addition the process of ozonation produces by-products that are themselves toxic and need to be treated. eXeno™ is an efficient post-treatment to remove toxicity from effluent wastewater.



AnoxServices: Certified testing for your wastewater

Based on more than 25 years of experience in R&D and laboratory tests, AnoxKaldnes can provide a complete screening of wastewater for more than 30 substances, design and optimise eXeno™ technology for both municipal and industrial wastewater.

Resourcing the world



Veolia - Water Tech trading as VWS (Ireland) Ltd.,
Dublin Road, Donaghcumpur, Celbridge, Kildare W23 AX07,
Ireland,
01 630 3333
www.veoliawatertechnologies.ie